Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Summary

The purpose of this study is to establish whether patients with malignancy harboring a discoidin domain receptor 2 mutation or an inactivating B-RAF mutation will respond to dasatinib.

Timeline

Start

2012-05-31

Primary completion

2014-07-23

Completion

2014-07-23

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of efficacy and slow accrual”

Drugs

Indications